Network meta-analysis of oral Chinese patent medicines for coronary heart disease with diabetes
This systematic review and network meta-analysis assessed the efficacy of various oral Chinese patent medicines combined with conventional Western therapy in patients with coronary heart disease complicated by diabetes mellitus. The analysis included data from 7,988 patients. The review compared these interventions against conventional Western therapy alone to determine relative efficacy across multiple secondary outcomes.
Shexiang Baoxin Pills combined with conventional Western medicine exhibited optimal efficacy for reducing triglycerides, improving high-density lipoprotein cholesterol, decreasing left ventricular end-systolic diameter, reducing angina pectoris frequency and duration, and lowering inflammatory markers including interleukin-6, tumor necrosis factor-alpha, high-sensitivity C-reactive protein, endothelin-1, fibrinogen, and malondialdehyde. Tongxinluo Capsules combined with conventional Western medicine achieved the best outcomes for clinical efficacy, reducing 2-hour postprandial blood glucose, improving left ventricular end-diastolic diameter, and increasing nitric oxide levels.
Yindan Xinnaotong Soft Capsules combined with conventional Western medicine showed the most prominent effects on increasing left ventricular ejection fraction, reducing whole blood high-shear and low-shear viscosity, and improving superoxide dismutase levels. Jinlida Granules combined with conventional Western medicine yielded the best results for reducing fasting blood glucose, low-density lipoprotein cholesterol, and total cholesterol. Guanxinning Tablets combined with conventional Western medicine demonstrated optimal efficacy for reducing glycated hemoglobin. Liuwei Dihuang Pills combined with conventional Western medicine achieved optimal efficacy for reducing the incidence of major adverse cardiovascular events. Yangxinshi Tablets combined with conventional Western medicine exhibited the most significant decrease in N-terminal pro-B-type natriuretic peptide. Danzhi Jiangtang Capsules combined with conventional Western medicine achieved the best outcomes for reducing total cholesterol.
The primary outcome was not reported in this analysis. The authors synthesized findings based on specific secondary outcomes such as glycemic control, lipid profiles, cardiac function, angina-related measures, inflammatory markers, endothelial function, hemorheological parameters, and major adverse cardiovascular events. Adverse reactions were listed as a secondary outcome category but specific rates were not detailed in the provided data. The practice relevance is restrained due to the heterogeneity of the Chinese patent medicines and the lack of reported primary outcomes or specific adverse event frequencies.
View Original Abstract ↓
Evolocumab reduces cardiovascular events in diabetes without known atherosclerosis
Evolocumab cuts heart events in high-risk diabetes patients
Related in Cardiology
From Other Specialties
